Bayer Switches Focus Of Recursion AI Pact To Oncology
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.